FDA Approves Exondys51
September 19, 2016
19.09.2016-Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51.
- The drug will be useful for DMD children with a confirmed deletion/mutation of Exon 51 only.
- Commercial sale of the drug will be launched soon in the U.S.
Please visit https://mdfindia.org/mdfdetails.php?pagetitle=Exondys%2051&&id=39 for more details.